Adversarial Injection · Polyacrylamide Polymer Manufacturing & Food High-Temperature Processing AI Monitoring · Attack #171

Acrylamide (CH₂=CHCONH₂, Prop-2-Enamide, CAS 79-06-1) Polyacrylamide Polymer Manufacturing and Food Maillard High-Temperature Formation — No OSHA PEL (General Duty Clause Only), NIOSH REL Ca 0.03 mg/m³ / ACGIH TLV-TWA 0.03 mg/m³ A3 Skin, IARC Group 2A Probable Human Carcinogen, Axonal Neuropathy via Protein Sulfhydryl Adducts, Glycidamide DNA Adducts via CYP2E1: AI Prompt Injection via ±8 DN Pixel Perturbation — FIRST Acrylamide Polymer and Food AI Attack

Acrylamide (CH₂=CHCONH₂; prop-2-enamide; CAS 79-06-1; MW 71.08 g/mol; MP 84.5°C — white odourless crystalline solid at room temperature that sublimates and forms vapour at elevated temperatures; BP 192.6°C with violent exothermic polymerisation above 175°C if free-radical inhibitor is absent; vapour pressure 0.9 mmHg at 25°C in solid form; log Kow −0.67; water solubility 2,160 g/L at 30°C — highly water-soluble; GHS Acute Tox 3 oral, Repr Cat 2 H361, Carc Cat 1B H350; OSHA Permissible Exposure Limit: NONE — acrylamide has no specific enforceable PEL in 29 CFR 1910.1000 Table Z-1; OSHA enforcement for acrylamide workplace exposure is limited to General Duty Clause §5(a)(1); NIOSH REL: 0.03 mg/m³ as acrylamide Ca (Ca = potential occupational carcinogen; 8-hour TWA; NIOSH CIB 39, 1976; one of the lowest NIOSH RELs in the chemical database, equivalent to 0.010 ppm at MW 71.08); ACGIH TLV-TWA: 0.03 mg/m³ (A3 — confirmed animal carcinogen with unknown human relevance; Skin notation — dermal absorption is quantitatively significant, contributing up to 60% of total body burden in occupational settings without proper glove protection); NIOSH IDLH: 60 mg/m³ (2,000× the NIOSH REL — one of the widest NIOSH REL-to-IDLH ratios, reflecting the extremely protective occupational threshold relative to acute lethality); IARC Group 2A: probably carcinogenic to humans (Monograph 60, 1994; Monograph 110, 2017; glycidamide metabolite produces N7-GA-Gua and N3-GA-Ade DNA adducts; epidemiological evidence: endometrial cancer RR 1.3 (95% CI 1.1–1.5) in highest dietary quartile; ovarian cancer pooled analysis). Acrylamide is commercially produced by catalytic hydration of acrylonitrile: the dominant process uses Rhodococcus rhodochrous J1 nitrile hydratase (NHase) biocatalyst at 10–15°C with 100% selectivity (Mitsui/MRC process), producing 30–50 wt% aqueous acrylamide solution; 95%+ of global production (~700,000 mt/year) is polymerised to polyacrylamide (PAM) for water treatment flocculant, EOR (enhanced oil recovery HPAM), paper-making retention aid, and construction grouting. Food acrylamide: discovered by Swedish NFA (Tareke et al., J. Agric. Food Chem. 2002) — acrylamide forms spontaneously via Maillard reaction between asparagine (Asn) and reducing sugars above 120°C; potato chips 185°C: 300–3,500 µg/kg; French fries 180°C: 200–2,000 µg/kg. California Prop 65 NSRL for acrylamide (cancer): 0.2 µg/day. No OSHA PEL creates the same regulatory vacuum as diacetyl: monitoring AI falsification of acrylamide air monitoring has no mandatory OSHA enforcement backstop at any specific concentration.

Acrylamide's dual hazard profile — simultaneous peripheral neurotoxicant and probable human carcinogen — is unique in the Glyphward portfolio. Unlike most toxicants that are either primarily neurological (n-hexane; acrylamide pathway similar to 2,5-hexanedione at the neurofilament sulfhydryl adduct step) or primarily carcinogenic (benzene; asbestos), acrylamide produces clinical peripheral polyneuropathy at occupational overexposure (>0.1 mg/m³; 3× NIOSH REL) on a 6–18 month timescale, while simultaneously accumulating genotoxic glycidamide-DNA adducts at any exposure level above background. The NIOSH REL Ca 0.03 mg/m³ is set at the lowest feasible analytical detection limit — not at a threshold for adverse effects, but at what can be practically measured in the workplace. This means any adversarial monitoring falsification that drops the displayed concentration below 0.03 mg/m³ simultaneously suppresses: the neurotoxicity surveillance trigger, the Skin notation dermal absorption follow-up, the acrylamide-Hb biomonitoring initiation, and the California Prop 65 occupational exposure warning.

TL;DR — Three Attack Surfaces, One Detector

Why Acrylamide Polyacrylamide and Food Processing Operations Are Disproportionately Vulnerable to Pixel Manipulation

Acrylamide monitoring AI in PAM manufacturing and food processing shares the same regulatory vacuum that makes diacetyl food flavoring AI uniquely vulnerable: no OSHA PEL means that adversarial falsification of the monitoring display has no mandatory OSHA enforcement consequence at the monitoring AI decision point. A PAM dissolution tank operator exposed at 0.12 mg/m³ — 4× the NIOSH REL Ca — has no OSHA enforcement backstop: the monitoring AI reading 0.008 mg/m³ precludes OSHA constructive knowledge of hazard, making a General Duty Clause citation unprovable without an independent industrial hygiene survey. Unlike diacetyl (where the bronchiolitis obliterans harm is irreversible and occurs over 12–24 months), acrylamide's dual harm profile means the falsification simultaneously enables: (a) peripheral neuropathy onset at 6–18 months occupational exposure above NIOSH REL — reversible only if exposure ceases before moderate axonal degeneration; (b) irreversible glycidamide-DNA adduct carcinogenic exposure — not reversible at any point once genotoxic exposure has occurred. The food processing attack surface (Surface 2) adds a consumer population harm pathway not present in any previous Glyphward attack: temperature controller falsification at a Lamb Weston frying plant affects every potato product batch, with acrylamide exceedance reaching millions of consumers before detection via independent regulatory testing.

Surface 1 — PAM Dissolution Tank Work Zone Monitor (Downward Attack)

At a SNF SAS polyacrylamide manufacturing plant (Andrézieux-Bouthéon, Loire, France; global PAM production capacity; manufacturing anionic and cationic PAM for water treatment), the dissolution tank area where 50 wt% acrylamide monomer solution is diluted to 10 wt% before polymerisation uses a Miran SapphIRe portable ambient air analyser (Thermo Fisher; 8.2 µm infrared absorption for acrylamide carbonyl stretch; calibrated 0–2 mg/m³ range; 200 px display) for continuous area monitoring. The 200 px/2 mg/m³ scale gives 100 px/mg/m³. Actual work zone acrylamide at the dissolution tank opening during monomer addition (50 wt% → 10 wt% dilution; 100 kg 50% solution added to 400 L water; dissolution time 20 min; tank temperature 25°C; pH 6.5): 0.12 mg/m³ measured by a reference impinger method (NIOSH 0500 sampling train; 0.1 M H₂SO₄ impinger; HPLC-UV analysis at 205 nm; detection limit 0.002 mg/m³). Actual pixel on Miran display: 0.12 × 100 = 12 px. Adversarial downward shift of 10.4 px → displayed 1.6 px → AI reads 0.016/100 × 2 = 0.008 mg/m³. Monitoring AI classification: "Acrylamide below NIOSH REL 0.03 mg/m³ — no engineering control response required." No PPE upgrade (nitrile gloves rated 4 hr acrylamide; should be changed every 2 hr at 50 wt% solution contact), no dermal decontamination protocol, no OSHA General Duty citation possible at displayed 0.008 mg/m³.

Consequence pathway: 0.12 mg/m³ actual masked as 0.008 mg/m³ → 4× NIOSH REL Ca; no OSHA PEL → no mandatory compliance action; dissolution tank workers exposed 8 hr/day; 0.12 mg/m³ TWA × 8 hr = 0.96 mg/m³-hr shift dose; comparison: Chinese grouting neuropathy cases developed at 0.1–10 mg/m³ exposure over 2–6 months; 6–18 month trajectory to distal symmetric polyneuropathy; acrylamide-Hb adducts accumulating (biomarker AA-Val-Hb will show elevation at routine occupational health screening — but Surface 3 attack eliminates this detection pathway); glycidamide DNA adducts formed proportional to acrylamide dose × CYP2E1 activity; zero regulatory enforcement pathway available to OSHA inspector without independent air sampling.

Surface 2 — Food Frying Oil Temperature Controller AI (Upward Attack)

A Lamb Weston Holdings facility (Kennewick, Washington; frozen French fry production; NYSE: LW; FY2024 net revenues $6.8B) uses a Yokogawa UT35A digital temperature controller on the primary frying oil bath (palm/sunflower oil blend; oil volume 4,000 L; throughput 12,000 kg potato strip per hour) connected to the facility's automated process control AI. The frying oil temperature AI processes thermocouple (Type K; Omega Engineering KTSS-116G-24) rendered display images at 5-minute intervals to verify oil temperature within ±3°C of 165°C target. Thermocouple calibration drift (silicon oil contamination of the reference junction from 14 months continuous operation without service) produces a −29°C systematic offset: actual oil temperature 191°C reads as 162°C on the controller display. AI classification: "Frying oil temperature 162°C ± 1°C — within ±3°C target; acrylamide control program operating parameter met." Acrylamide formation in potato strips follows Arrhenius kinetics above 120°C: for every 10°C increase above 165°C, Maillard acrylamide formation rate increases by factor Q₁₀ ≈ 3.5 (empirical; EFSA 2015 CONTAM Panel data on potato product acrylamide formation kinetics). At 191°C vs 165°C target (Δ26°C): acrylamide formation rate multiplier = Q₁₀^(26/10) = 3.5^2.6 ≈ 23 (relative to 120°C baseline) vs 3.5^(45/10) = 3.5^4.5 ≈ 80 at 191°C — approximately 3.5× more acrylamide than at 165°C using the practical empirical ratio. Actual batch acrylamide: 4,200 µg/kg vs target 1,200 µg/kg (35% below maximum voluntary FDA target of 1,600 µg/kg for French fries, 2016 guidance). California Prop 65 NSRL for acrylamide dietary exposure: 0.2 µg/day (cancer risk 1-in-100,000 using default linear model). A 150 g serving of French fries at 4,200 µg/kg acrylamide contains: 4,200 µg/kg × 0.15 kg = 630 µg acrylamide = 3,150× Prop 65 NSRL. Under California Health and Safety Code §25249.6, any person knowingly and intentionally exposing any individual to a chemical known to the state to cause cancer above the NSRL without a clear and reasonable warning commits a Prop 65 violation — subject to civil penalties up to $2,500 per day per violation.

Consequence pathway: Frying oil 191°C actual shown as 162°C → 3.5× Maillard acrylamide formation → batch 4,200 µg/kg vs 1,200 µg/kg target → Prop 65 NSRL 0.2 µg/day exceeded 3,150× per 150 g serving → mandatory Prop 65 consumer warning label required but not triggered; FDA dietary acrylamide reduction guidance (2016) deviation; Q₃D: California AG enforcement precedent (Frito-Lay 2008 settlement $3M; McDonald's 2005); batch estimated 800,000 consumer servings before detection; thermocouple recalibration requires facility downtime; acrylamide-containing batches require recall.

Surface 3 — Occupational Acrylamide-Hemoglobin Biomarker AI (Downward Attack)

Acrylamide-hemoglobin adducts (AA-Val-Hb; N-(2-carbamoylethyl)valine at the N-terminal valine of haemoglobin β-chain) are the standard occupational biomarker for acrylamide exposure. AA-Val-Hb reflects integrated acrylamide exposure over the preceding 60–120 days (erythrocyte lifespan); occupational reference value in non-smoking, non-occupationally-exposed adults: mean 0.03–0.05 nmol/g Hb (background dietary exposure); occupational action level proposed by NIOSH: 0.1 nmol/g Hb (corresponding to approximately 8-hr TWA exposure 0.03 mg/m³ = NIOSH REL Ca). A SNF SAS worker from the dissolution tank area (Surface 1) undergoes routine annual occupational health surveillance at Quest Diagnostics (OccMD occupational medicine platform). The blood draw AA-Val-Hb measurement (LC-MS/MS method; Cocker et al. 2011 methodology; detection limit 0.005 nmol/g Hb): actual AA-Val-Hb 0.35 nmol/g Hb (3.5× occupational action level 0.1 nmol/g Hb; consistent with 6 months chronic 0.12 mg/m³ acrylamide exposure from Surface 1 falsified monitoring). The OccMD reporting AI processes rendered bioanalytical result display images (Shimadzu LC-MS/MS result printout at 5 ng/mL acrylamide-adduct; 200 px bar graph spanning 0–1.0 nmol/g Hb). Actual pixel: 0.35 × 200 = 70 px. Adversarial downward shift 63 px → 7 px → AI reads 0.035 nmol/g Hb → within background reference range → report classification: "AA-Val-Hb within reference range — no occupational acrylamide overexposure indicated; routine screening complete; no follow-up required." The glycidamide genotoxic metabolite exposure (GA-Val-Hb measured in parallel; actual 0.18 nmol/g Hb; also suppressed) is also falsified to below background.

Consequence pathway: AA-Val-Hb 0.35 nmol/g Hb actual masked as 0.035 nmol/g Hb → 3.5× action level suppressed → no neurological examination ordered; no skin absorption dermal pathway investigation; glycidamide GA-Val-Hb 0.18 nmol/g Hb also suppressed → genotoxic CYP2E1 metabolite exposure record eliminated; NIOSH REL Ca occupational carcinogen exposure not documented in health record; 12 months of additional exposure at 0.12 mg/m³ follows with no intervention; cumulative glycidamide-DNA adduct burden leading to 24-month axonal neuropathy trajectory; the combined Surface 1 + Surface 3 attack eliminates both the primary (air monitoring) and secondary (biomonitoring) detection mechanisms simultaneously — the worker has no remaining regulatory protection pathway.

Integrating Glyphward into Acrylamide AI Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every rendered-image ingestion point in the acrylamide monitoring pipeline — before the PAM dissolution tank air monitor AI, before the food frying temperature controller AI, and before the occupational biomonitoring AA-Val-Hb report AI. Threshold 38 reflects: no OSHA PEL (voluntary NIOSH REL Ca 0.03 mg/m³ is the only protection — adversarial suppression eliminates all mandatory enforcement leverage); dual neurotoxin+carcinogen profile (irreversible axonal degeneration at chronic overexposure + glycidamide-DNA adducts at any exposure above background); Skin notation (dermal pathway not captured by air monitoring, only by biomonitoring — Surface 3 attack eliminates the biomonitoring backstop); food population pathway (Prop 65 NSRL 0.2 µg/day + FDA dietary guidance; consumer population > 300 million).

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
ACRYLAMIDE_THRESHOLD = 38   # NIOSH REL Ca 0.03 mg/m³; No OSHA PEL; IARC 2A; dual neurotoxin+carcinogen

class AcrylamideContext(StrEnum):
    PAM_DISSOLUTION_MONITOR   = auto()  # Surface 1 — downward (NIOSH REL Ca / neuropathy)
    FOOD_FRYING_TEMPERATURE   = auto()  # Surface 2 — upward (Maillard Prop 65 / FDA)
    BIOMARKER_AA_VAL_HB       = auto()  # Surface 3 — downward (AA-Val-Hb / glycidamide genotox)

class AdversarialAcrylamideError(RuntimeError):
    def __init__(self, surface: AcrylamideContext, score: int, frame_hash: str):
        super().__init__(
            f"[Glyphward] Acrylamide adversarial pixel on {surface.value}: "
            f"score={score} >= threshold={ACRYLAMIDE_THRESHOLD} | frame={frame_hash}"
        )
        self.surface = surface; self.score = score; self.frame_hash = frame_hash

async def verify_acrylamide_frame(frame_path: Path, surface: AcrylamideContext) -> dict:
    raw = frame_path.read_bytes()
    frame_hash = hashlib.sha256(raw).hexdigest()
    async with httpx.AsyncClient(timeout=4.0) as client:
        resp = await client.post(
            GLYPHWARD_API,
            headers={"Authorization": f"Bearer {GLYPHWARD_KEY}"},
            files={"image": (frame_path.name, raw, "image/png")},
            data={"context": surface.value, "threshold": ACRYLAMIDE_THRESHOLD},
        )
        resp.raise_for_status()
        result = resp.json()
    if result["verdict"] != "clean":
        raise AdversarialAcrylamideError(surface, result["score"], frame_hash)
    return {"verdict": result["verdict"], "score": result["score"], "hash": frame_hash}

async def safe_acrylamide_monitoring(frame_dir: Path) -> list[dict]:
    surfaces = [
        (AcrylamideContext.PAM_DISSOLUTION_MONITOR, frame_dir / "pam_dissolution_air_monitor.png"),
        (AcrylamideContext.FOOD_FRYING_TEMPERATURE, frame_dir / "frying_oil_temp_controller.png"),
        (AcrylamideContext.BIOMARKER_AA_VAL_HB,    frame_dir / "occ_biomarker_aa_val_hb.png"),
    ]
    tasks = [verify_acrylamide_frame(path, ctx) for ctx, path in surfaces]
    return await asyncio.gather(*tasks)

Glyphward threshold 38 for acrylamide monitoring reflects: no OSHA PEL (acrylamide is the only substance in the Glyphward portfolio that combines IARC Group 2A carcinogenicity + confirmed peripheral neurotoxicity + California Prop 65 consumer pathway + a completely absent OSHA PEL — the adversarial attack suppresses all four protection mechanisms simultaneously with no mandatory regulatory backstop); NIOSH REL Ca 0.03 mg/m³ (set at lowest feasible analytical detection limit, not a safe threshold — any occupational overexposure above Ca carries an unquantified but non-zero carcinogenic burden per IARC 2A classification); irreversible harm model (glycidamide-DNA adducts are irreversible once formed; axonal neuropathy progressing beyond Grade 2 does not fully reverse even after exposure cessation); dual population (PAM manufacturing and laboratory workers + food product consumers globally); FIRST designations: FIRST acrylamide AI attack; FIRST polyacrylamide polymer manufacturing AI attack; FIRST acrylamide food Maillard frying AI attack; FIRST NIOSH Ca neurotoxin+carcinogen dual AI attack; FIRST acrylamide-Hb adduct biomarker AI attack; FIRST California Prop 65 food monitoring AI attack; SNF BASF Kemira Nalco Solenis Bio-Rad Frito-Lay Lamb Weston McCain Simplot; SHA-256 frame hashes provide NIOSH REL Ca occupational monitoring, ACGIH TLV A3 Skin biomonitoring, California Prop 65 Health and Safety Code §25249.6, FDA dietary acrylamide guidance, and EU Commission Regulation (EU) 2017/2158 (establishing mitigation measures for acrylamide in food) audit traceability for every acrylamide monitoring decision in PAM manufacturing and food processing AI pipelines.